Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319541 | 0.93 | DDB1 (0.46) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL23319554 | 0.91 | DDB1 (0.44) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL29945240 | 0.91 | DDB1 (0.44) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL27085652 | 0.90 | DDB1 (0.55) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL21070560 | 0.89 | DDB1 (0.46) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL27085646 | 0.89 | DDB1 (0.54) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL23319510 | 0.89 | P2RX4 (0.49) | MAPTMEN1KMT2ALMNAP2RX4 | |
| SCHEMBL30036237 | 0.89 | P2RX4 (0.49) | MAPTMEN1KMT2ALMNAP2RX4 | |
| SCHEMBL21070398 | 0.88 | MAPT (0.41) | MAPTMEN1KMT2ATHRBLMNA | |
| SCHEMBL31664208 | 0.88 | MAPT (0.41) | MAPTMEN1KMT2ATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220348556-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3817822-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3817748-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | MAPT 1069/4885MEN1 3164/4885KMT2A 1863/4885 |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | CRBN, CRKL, CUL4A | MAPT 1069/4885MEN1 3164/4885KMT2A 1863/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | MAPT 1069/4885MEN1 3164/4885KMT2A 1863/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | MAPT 489/4885MEN1 2643/4885KMT2A 1723/4885 |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | SRR, SRRM2, CRBN | MAPT 3533/4885MEN1 4489/4885KMT2A 2615/4885 |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | MAPT 1069/4885MEN1 3164/4885KMT2A 1863/4885 |
| US-20220348556-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | MAPT 489/4885MEN1 2643/4885KMT2A 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.